Holen Sie sich die Stockscreener-App
53.72
0.96%
0.51
Vorhandelsmarkt:
53.72
Schlusskurs vom Vortag:
$53.21
Offen:
$53.22
24-Stunden-Volumen:
753.97K
Relative Volume:
0.40
Marktkapitalisierung:
$10.03B
Einnahmen:
$516.85M
Nettoeinkommen (Verlust:
$174.11M
KGV:
61.75
EPS:
0.87
Netto-Cashflow:
$217.38M
1W Leistung:
+3.11%
1M Leistung:
+1.94%
6M Leistung:
+85.31%
1J Leistung:
+82.35%
1-Tages-Spanne:
$52.95
$54.43
1-Wochen-Bereich:
$49.01
$54.43
52-Wochen-Spanne:
$22.96
$61.75
Doximity Inc Stock (DOCS) Company Profile
Firmenname
Doximity Inc
Sektor
Branche
Telefon
(650) 549-4330
Adresse
500 THIRD STREET, SAN FRANCISCO
Vergleichen Sie DOCS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
DOCS
Doximity Inc
|
53.72 | 10.03B | 516.85M | 174.11M | 217.38M | 0.87 |
|
VEEV
Veeva Systems Inc
|
216.59 | 35.16B | 2.66B | 665.91M | 1.08B | 4.05 |
|
SOLV
Solventum Corp
|
73.51 | 12.70B | 8.26B | 66.00M | 1.17B | 0.3682 |
|
HQY
Healthequity Inc
|
102.42 | 8.88B | 1.15B | 96.70M | -161.99M | 1.09 |
|
WAY
Waystar Holding Corp
|
37.47 | 6.45B | 906.14M | -52.62M | 89.62M | -0.3621 |
Doximity Inc Stock (DOCS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-20 | Eingeleitet | Stephens | Equal-Weight |
| 2024-12-04 | Eingeleitet | Mizuho | Neutral |
| 2024-11-15 | Eingeleitet | Goldman | Neutral |
| 2024-11-14 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2024-11-13 | Herabstufung | Canaccord Genuity | Buy → Hold |
| 2024-11-08 | Hochstufung | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2024-11-08 | Hochstufung | Wells Fargo | Underweight → Equal Weight |
| 2024-10-15 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2024-08-09 | Hochstufung | Needham | Hold → Buy |
| 2024-07-18 | Herabstufung | Wells Fargo | Equal Weight → Underweight |
| 2024-04-25 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2024-02-26 | Eingeleitet | Leerink Partners | Market Perform |
| 2024-01-03 | Eingeleitet | Barclays | Equal Weight |
| 2024-01-02 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2023-08-09 | Herabstufung | Guggenheim | Buy → Neutral |
| 2023-08-09 | Herabstufung | Needham | Buy → Hold |
| 2023-08-03 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2023-05-01 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2023-01-06 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2022-10-31 | Eingeleitet | Wells Fargo | Overweight |
| 2022-10-24 | Eingeleitet | Evercore ISI | In-line |
| 2022-10-13 | Eingeleitet | BTIG Research | Neutral |
| 2022-09-16 | Eingeleitet | KeyBanc Capital Markets | Sector Weight |
| 2022-09-07 | Eingeleitet | Truist | Hold |
| 2022-08-05 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2022-07-28 | Eingeleitet | Berenberg | Buy |
| 2022-05-18 | Bestätigt | BofA Securities | Neutral |
| 2022-05-18 | Bestätigt | Goldman | Buy |
| 2022-05-18 | Bestätigt | Guggenheim | Buy |
| 2022-05-18 | Bestätigt | Jefferies | Buy |
| 2022-05-18 | Bestätigt | Morgan Stanley | Equal-Weight |
| 2022-05-18 | Bestätigt | Needham | Buy |
| 2022-04-07 | Eingeleitet | Guggenheim | Buy |
| 2022-04-04 | Eingeleitet | BofA Securities | Neutral |
| 2022-02-11 | Eingeleitet | Goldman | Buy |
| 2021-12-14 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2021-12-02 | Eingeleitet | Jefferies | Buy |
| 2021-11-17 | Eingeleitet | Robert W. Baird | Outperform |
| 2021-11-10 | Bestätigt | Canaccord Genuity | Buy |
| 2021-11-10 | Bestätigt | Goldman | Neutral |
| 2021-11-10 | Bestätigt | Morgan Stanley | Equal-Weight |
| 2021-11-10 | Bestätigt | Needham | Buy |
| 2021-11-10 | Bestätigt | Piper Sandler | Overweight |
| 2021-08-26 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2021-07-19 | Eingeleitet | Canaccord Genuity | Buy |
| 2021-07-19 | Eingeleitet | Goldman | Neutral |
| 2021-07-19 | Eingeleitet | JP Morgan | Overweight |
| 2021-07-19 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2021-07-19 | Eingeleitet | Piper Sandler | Overweight |
| 2021-07-19 | Eingeleitet | Raymond James | Outperform |
| 2021-07-19 | Eingeleitet | SVB Leerink | Outperform |
| 2021-07-19 | Eingeleitet | William Blair | Outperform |
Alle ansehen
Doximity Inc Aktie (DOCS) Neueste Nachrichten
Wedmont Private Capital Acquires Shares of 5,726 Doximity, Inc. (NASDAQ:DOCS) - MarketBeat
Doximity to Release Fiscal 2025 Third Quarter Results on February 6, 2025 - Marketscreener.com
DOCSDoximity, Inc. Latest Stock News & Market Updates - StockTitan
Doximity Sets Date for Q3 FY2025 Earnings Release and Conference Call on February 6 - StockTitan
Do Doximity's (NYSE:DOCS) Earnings Warrant Your Attention? - Yahoo Finance
26,072 Shares in Doximity, Inc. (NASDAQ:DOCS) Acquired by Hamilton Lane Advisors LLC - MarketBeat
33,902 Shares in Doximity, Inc. (NASDAQ:DOCS) Purchased by Burney Co. - MarketBeat
Apella Capital LLC Boosts Holdings in Doximity, Inc. (NASDAQ:DOCS) - MarketBeat
3 Telemedicine Stocks Making Healthcare More Accessible - Inkl
DOCS: 3 Telemedicine Stocks Making Healthcare More Accessible - StockNews.com
David J Yvars Group Acquires Shares of 20,966 Doximity, Inc. (NASDAQ:DOCS) - MarketBeat
FNY Investment Advisers LLC Makes New Investment in Doximity, Inc. (NASDAQ:DOCS) - MarketBeat
Spotting Winners: Doximity (NYSE:DOCS) And Vertical Software Stocks In Q3 - Yahoo Finance
Doximity Inc (DOCS) Trading Down 5.45% on Jan 13 - GuruFocus.com
Demystifying Doximity: Insights From 15 Analyst Reviews - Benzinga
Doximity (NASDAQ:DOCS) Stock Price Expected to Rise, Wells Fargo & Company Analyst Says - MarketBeat
Doximity: Upgraded To Buy Amid Promising Growth And Strong Execution - Seeking Alpha
JPMorgan Chase & Co. Increases Position in Doximity, Inc. (NASDAQ:DOCS) - MarketBeat
Doximity (NASDAQ:DOCS) Price Target Lowered to $65.00 at KeyCorp - MarketBeat
Looking Into Doximity's Recent Short InterestDoximity (NYSE:DOCS) - Benzinga
Doximity (DOCS) Stock Moves -0.16%: What You Should Know - MSN
Doximity (NASDAQ:DOCS) Price Target Raised to $57.00 at Bank of America - MarketBeat
Here's Why We Think Doximity (NYSE:DOCS) Is Well Worth Watching - Simply Wall St
The Zacks Analyst Blog Highlights Doximity, BrightSpring Health Services and Embecta - Yahoo Finance
Doximity (DOCS) Stock Moves -0.13%: What You Should Know - MSN
Doximity (NASDAQ:DOCS) Shares Down 5%Time to Sell? - MarketBeat
Principal Financial Group Inc. Reduces Holdings in Doximity, Inc. (NASDAQ:DOCS) - MarketBeat
Doximity, Inc. (NASDAQ:DOCS) Given Average Rating of "Hold" by Brokerages - MarketBeat
Barclays PLC Has $2.33 Million Stock Holdings in Doximity, Inc. (NASDAQ:DOCS) - MarketBeat
Franklin Resources Inc. Raises Stock Position in Doximity, Inc. (NASDAQ:DOCS) - MarketBeat
Doximity (DOCS) Ascends But Remains Behind Market: Some Facts to Note - MSN
Why Doximity Inc. (DOCS) Skyrocketed? - Insider Monkey
Why Did Doximity Inc. (DOCS) Jump Yesterday? - MSN
Forecasting The Future: 15 Analyst Projections For Doximity - Benzinga
Doximity (NASDAQ:DOCS) Coverage Initiated at Stephens - MarketBeat
Doximity's SWOT analysis: digital health leader faces growth challenges By Investing.com - Investing.com Canada
DOXIMITY ALERT: Bragar Eagel & Squire, P.C. is - GlobeNewswire
Doximity (NASDAQ:DOCS) Stock Price Up 4.9%Time to Buy? - MarketBeat
Doximity's SWOT analysis: digital health leader faces growth challenges - Investing.com
Doximity, Inc.'s (NYSE:DOCS) Stock's On An Uptrend: Are Strong Financials Guiding The Market? - Simply Wall St
Is biote Corp. (BTMD) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
Geode Capital Management LLC Has $124.50 Million Holdings in Doximity, Inc. (NASDAQ:DOCS) - MarketBeat
Doximity, Inc. (NASDAQ:DOCS) Stake Cut by HighTower Advisors LLC - MarketBeat
Doximity Report Confirms That Telemedicine Serves Key Role in Modern Health Care - Business Wire
The Zacks Analyst Blog Highlights McKesson, Doximity and Veracyte - Yahoo Finance
Lord Abbett & CO. LLC Makes New Investment in Doximity, Inc. (NASDAQ:DOCS) - MarketBeat
Doximity's SWOT analysis: stock faces growth challenges amid strong margins - Investing.com
Finanzdaten der Doximity Inc-Aktie (DOCS)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.33%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):